Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
October 07, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
September 12, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
August 21, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
August 14, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
August 09, 2024 08:00 ET
|
Monopar Therapeutics Inc.
Initiated and Enrolling Patients into MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101 radio-immuno-therapeutic (RIT) Clinical Trial on Track to Initiate in Q4 2024 ...
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
July 09, 2024 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
June 25, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients,...
Monopar and NorthStar Amend & Extend Collaboration
June 11, 2024 07:30 ET
|
Monopar Therapeutics Inc.
Highlights: Builds on Companies’ respective core strengthsAligns intellectual property rightsEstablishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s...
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
June 10, 2024 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer...